The FDA has approved Vabysmo for the treatment of wet age-related macular degeneration and diabetic macular edema, according to a press release from Genentech.
Vabysmo (faricimab-svoa) is an injectable eye medicine that works by targeting and inhibiting Ang-2 and VEGF-A pathways.
“Vabysmo represents an important step forward for ophthalmology. It is the first bispecific antibody approved for the eye and a major advance in treating retinal conditions such as wet AMD and diabetic macular edema,” Charles C. Wykoff, MD, PhD, director of research at Retina Consultants of Texas in Houston